title: Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats.
abstract: OBJECTIVE
  The present study was designed to evaluate whether long-term resveratrol administration has beneficial effects on the metabolic control and oxidative stress in diabetic rats.
  
  
  METHODS
  Male Wistar rats were divided into four groups: normal control, diabetic control, normal treated with resveratrol, and diabetic treated with resveratrol. Diabetes was induced by injection of streptozotocin (50 mg/kg; i.p.), fifteen minutes after the administration of nicotinamide (110 mg/kg; i.p.) in 12 h fasted rats.
  
  
  RESULTS
  Four-month oral resveratrol administration (5 mg/kg/day) significantly attenuated the elevated levels of the blood glucose, glycosylated hemoglobin, total protein, albumin, urea, creatinine, and 8-isoprostane in diabetic rats. Moreover, resveratrol administration to diabetic rats improved the reduced levels of glutathione, total antioxidant capacity, and the antioxidant enzymes activities (superoxide dismutase, glutathione peroxidase, and catalase). No significant differences were observed in the activities of plasma aminotransferases (ALT and AST) and insulin levels between diabetic rats treated with resveratrol and diabetic controls.
  
  
  CONCLUSIONS
  The results suggest that chronic resveratrol administration is safe and effective, and may be considered as a beneficial therapeutic compound in diabetes.
authors.affiliation: Department of Physiology, Hormozgan University of Medical Sciences, Bandar Abbas. Soufifg@tbzmed.ac.ir
authors.forename: F G
authors.initials: FG
authors.lastname: Soufi
authors.forename: R
authors.initials: R
authors.lastname: Sheervalilou
authors.forename: M
authors.initials: M
authors.lastname: Vardiani
authors.forename: M
authors.initials: M
authors.lastname: Khalili
authors.forename: M R
authors.initials: MR
authors.lastname: Alipour
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001219:Aspartate Aminotransferases / Q000097:blood; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D005979:Glutathione Peroxidase / Q000378:metabolism; D006943:Hyperglycemia / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism; D000094765:Glutathione Peroxidase GPX1
chemical_list: D000975:Antioxidants; D013267:Stilbenes; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000077185:Resveratrol; D000094765:Glutathione Peroxidase GPX1; C000722069:Gpx1 protein, rat